载体介导的细粒棘球绦虫Eg95疫苗的研制现状  

Development status of vector-mediated Eg95 vaccine of Echinococcus granulosus

作　　者：李文桂[1] 陈雅棠[1] Li Wengui;Chen Yatang(Institute of Infections and Parasitic Diseases,the First Hospital Affiliated of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院传染病寄生虫病研究所,重庆400016

出　　处：《中华地方病学杂志》2023年第8期684-688,共5页Chinese Journal of Endemiology

基　　金：国家自然科学基金(30801052、30671835、30500423、30200239)。

摘　　要：由细粒棘球绦虫(Eg)续绦期幼虫引起的囊型棘球蚴病(CE)是目前我国重点防控的寄生虫病之一。Eg95蛋白是一种公认的疫苗候选分子,研制载体介导的Eg95疫苗是当前CE研究热点之一。本文概述了牛痘病毒、羊口疮病毒、山羊痘病毒、狂犬病毒、鼠伤寒沙门菌、卡介苗、根癌农杆菌和两歧双歧杆菌等载体介导的Eg95疫苗的研制现状,旨在为CE的免疫预防研究提供有价值的资料。Cystic echinococcosis(CE),caused by the larva of Echinococcus granulosus(Eg),is one of the key parasitic diseases to prevent and control in China.The Eg95 protein is a recognized vaccine candidate molecule,and the development of vector-mediated Eg95 vaccine is one of the current research hotspots in CE.This article summarizes the development status of Eg95 vaccine such as vaccinia virus,orf virus,goatpox virus,rabies virus,Salmonella typhimurium,Bacille Calmette-Guerin,Agrobacterium tumefaciens and Bifidobacteria bifidum,in order to provide valuable information for the immune prevention of CE.

关 键 词：细粒棘球绦虫 Eg95蛋白 疫苗 

分 类 号：R392[医药卫生—免疫学]